What is Ava?
Ava is a specialized digital health enterprise headquartered in Zurich, with an expansive international footprint including offices in San Francisco, Belgrade, and Makati. The company sits at the intersection of artificial intelligence and clinical research, focusing specifically on women's reproductive health. Its flagship product, a fertility tracking sensor bracelet, utilizes advanced algorithms to detect the five most fertile days of a woman's cycle with 90% accuracy. By providing real-time, personalized insights into reproductive health and pregnancy, Ava has established itself as a critical innovator in the healthtech landscape, effectively bridging the gap between consumer-grade wearables and clinical-grade diagnostic data.
How much funding has Ava raised?
Ava has raised a total of $42.3M across 3 funding rounds:
Angel/Seed
$2.6M
Series A
$9.7M
Series B
$30M
Angel/Seed (2015): $2.6M with participation from Swisscom and Zu00fcrcher Kantonalbank
Series A (2016): $9.7M led by Global Sources, Polytech Ventures, Blue Ocean Ventures, Swisscom, and Zurich Cantonal Bank
Series B (2018): $30M supported by Global Sources, btov, Polytech Ventures, Blue Ocean Ventures, SVC Ltd., Swisscom, and Zurich Cantonal Bank
Key Investors in Ava
Swisscom
Headquartered in Worblaufen, Switzerland, Swisscom is a Swiss telecommunications provider, majority-owned by the Swiss Confederation. The company provides fixed-line and mobile phone service, broadband data, and cable TV to individuals and businesses.
Zürcher Kantonalbank
Zürcher Kantonalbank is a leading universal bank headquartered in Switzerland, serving the Zurich economic area with both Swiss roots and international reach. The institution offers a comprehensive range of financial products including business financing and asset management.
Global Sources
Global Sources is an internationally recognized B2B sourcing platform that has been driving global trade for over 50 years, connecting authentic buyers and verified suppliers worldwide through digital platforms and trade intelligence.
What's next for Ava?
Following its recent capital raise, Ava is well-positioned to accelerate its product development and expand its reach within the global digital health market. The infusion of resources will likely support the refinement of its AI-driven insights and the potential integration of new diagnostic capabilities. As the company transitions into a more mature phase of its lifecycle, the focus will likely shift toward deepening its clinical partnerships and scaling its user base across diverse international markets. By leveraging its existing network of strategic investors, Ava is poised to maintain its competitive edge in the rapidly evolving femtech industry, potentially setting new standards for data-driven reproductive health management.
See full Ava company page
